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Abstract 
 
Objective: 
&ĂďƌǇ ĚŝƐĞĂƐĞ ŝƐ Ă ƌĂƌĞ ŝŶŚĞƌŝƚĞĚ ůǇƐŽƐŽŵĂů ƐƚŽƌĂŐĞ ĚŝƐŽƌĚĞƌ ĐĂƵƐĞĚ ďǇ ĚĞĨŝĐŝĞŶĐǇ ŽĨ ɲ-
galactosidase A. Effective enzyme replacement therapies are available that are administered 
intravenously (IV).  However, a new oral treatment is being developed as an alternative option 
for patients with amenable mutations. This study was designed to understand the value that 
people place on the different features of treatments for Fabry disease.   
 
Research design and methods: 
A discrete choice experiment (DCE) was designed to assess the importance of different aspects 
of treatments for Fabry disease. The attributes included overall survival, mode of 
administration, treatment related reactions, treatment related headaches and risk of antibody 
formation. Attributes were combined using a published orthogonal array into choice sets. A 
research panel was used to survey the UK general public. The mixed logit model was used to 
estimate strength of preference for the attributes and marginal rates of substitution (MRS). 
Disutilities were estimated from the DCE data for changes in each attribute. 
 
Results: 
The sample (n=506) were broadly representative of UK demographics. The logit model revealed 
that all attributes were significant predictors of choice. Participants were significantly more 
likely to choose a treatment which meant an increase in their life expectancy by 1 year (Odds 
Ratio = 1.574; 95%CI=1.504-1.647) and significantly less likely to choose self-administered IV 
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treatment compared to an every other day tablet (OR= 0.426 95%CI=0.384-0.474). Estimated 
disutilities were -0.0543 (self-administered infusion), treatment related headaches 12 times a 
year (-0.0361) and infusion reactions 6 times a year (-0.0202).  
 
Conclusions: 
The survey revealed a significant preference for oral treatment compared with IV even in the 
context of a treatment that can extend overall survival. MRS were used as a basis for estimating 
disutilities associated with changes in attribute levels which could be used to weight QALYs.  It is 
possible that other important treatment attributes are missing from this research which may 
have provided further insights.  It would also be useful to extend this research to include Fabry 
disease patients so their preferences can be assessed against the societal perspective.    
 
Keywords 
Fabry disease, health related quality of life, cost-utility analysis, discrete choice 
experiment  
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Introduction 
Fabry disease is an inherited lysosomal storage disorder caused by deficiency of the enzyme 
ɲ-galactosidase A, which leads to the accumulation of globotriaosylceramide and other 
products in the lysosomes of cells. Over time this leads to progressive and irreversible organ 
damage, typically involving the kidney, heart and nervous system
1,2
. Fabry disease is a rare 
disease with a worldwide prevalence of approximately 1 in 40,000 to 1 in 117,000
3,4
 
although new born screening suggests possible incidence rate of up to 1:2000.  Current 
treatment consists of enzyme replacement therapies (ERT), administered intravenously (IV), 
which can be time consuming and disruptive for patients. In addition, patients can 
experience reactions to infusions such as rashes, tolerability, anaphylaxis and antibody 
formation.  A new treatment based on small molecule technology has recently been 
licenced which offers a completely new mode of action and can be taken orally.  Such 
treatments allow patients to avoid some problems with ERT, but may be associated with 
other side effects.   
In the context of such a severe condition as Fabry disease, the mode of administration of a 
treatment and the avoidance of mild but bothersome side effects may seem 
inconsequential.  However, it is worth considering that patients have to take the treatment 
for the rest of their lives and so issues of convenience and bother may become quite 
important for them.  As more treatment options for Fabry disease patients emerge, 
physicians and other decision makers will start to consider the value of treatments beyond 
their efficacy.  One way to consider this is if two treatments have equal efficacy then what 
other factors should be considered when making treatment decisions.  This report describes 
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an attempt to capture the relative importance of these other factors using a stated 
preference survey.   
 
Stated preference surveys such as discrete choice experiments (DCE) provide insight into 
the value that people place on different aspects of treatments or other health care 
interventions
5
.  DCE surveys can provide information about the relative importance of 
different treatment attributes (such as treatment effectiveness, mode of administration or 
risk of side effects). A DCE survey typically asks participants to consider pairs (or triplets) of 
hypothetical treatment choices and simply indicate which they prefer.  The treatment 
choices are defined in terms of specific attributes which are in turn characterized by distinct 
levels. The attributes and their levels are combined into choices using a statistical design 
which ensures that the combinations are orthogonal.  The results provide information 
regarding the relative importance of the attributes and also the extent to which participants 
are willing to trade a worse level of one attribute to achieve a better level of another.  
 
Recent work by a number of groups has employed these methods to explore whether 
people are willing to trade aspects of quality of life against length of life using DCE 
methods
6,7
.  DCE methods have also been used to provide health related quality of life 
(HRQL) weights for the widely used EQ-5D-5L
6,8
.  Similar methods were applied here in an 
attempt to estimate HRQL weights for Fabry disease which could be used in a cost-utility 
analysis.   
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In the present study we aimed to understand the views of the general public regarding 
treatments for Fabry disease and also the value that they place on innovations in treatment.   
 
The study had three main objectives: 
 
1. Understand ƉĂƌƚŝĐŝƉĂŶƚƐ ? ƐƚƌĞŶŐƚŚ ŽĨ ƉƌĞĨĞƌĞŶĐĞ ĨŽƌ ĚŝĨĨĞƌĞŶƚ ĂƚƚƌŝďƵƚĞƐ ŽĨ
treatments for Fabry disease. 
2. Explore the extent to which people are willing to trade between the different 
attributes of treatment 
3. Estimate HRQL weights for Fabry disease which could be used in a cost-utility 
analysis.   
 
Patients and methods 
 
Survey development 
Attributes for inclusion in the DCE survey were identified from the profiles of existing 
treatments for Fabry disease as well as the target profile for a new treatment for Fabry 
disease.  This was captured from the published Summary of Product Characteristics from 
the European Medicines Authority (EMA).  At the time the project was undertaken two 
treatments had marketing authorization from the EMA  ? Fabrazyme9 and Replagal10.  A 
third treatment, Migalastat was under review for marketing approval (and has now been 
approved by the EMA).  What were perceived to be the most important treatment 
attributes were identified by the clinical expert (DH) for inclusion in the survey.  A decision 
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was made to focus on attributes of treatments for which there was evidence of a difference 
between the three treatments.  So general issues which affect people with Fabry disease 
such as pain or the risk of dialysis in the future were not included because there was no 
evidence that any treatment was more beneficial in that regard.  The attributes selected for 
inclusion in the survey included 1) hypothetical effects on survival, 2) treatment 
effectiveness, 3) route of administration (tablet or infusion), 4) side effects, and 5) 
hypothetical risks associated with long-term use of treatment (e.g. risk of antibody 
formation).   
Treatment effectiveness was described in terms of overall life expectancy.  Fabry disease 
shorteŶƐƉĂƚŝĞŶƚƐ ?ŽǀĞƌĂůůƐƵƌǀŝǀĂůĂŶĚƚŚĞĞŶǌǇŵĞƌĞƉůĂĐĞŵĞŶƚƚŚĞƌĂƉŝĞƐŚĂǀĞďĞĞŶƐŚŽǁŶ
to be effective in improving overall survival
11
.  Although there is no clear evidence that any 
one treatment in Fabry disease is more effective than others for reducing mortality and 
morbidity
12
, including hypothetical effects on survival in the survey allowed exploration of 
the importance of the relative importance of survival compared to the other attributes.  
This was also done to estimate HRQL weights.   
The route of administration attribute described actual differences between the treatments.  
The attributes regarding treatment reactions and headache reflect side effects that people 
may experience with these treatments.  Treatment reactions are primarily associated with 
IV therapies in Fabry disease.  Headaches have been reported as a very common adverse 
reaction following treatment with migalastat
13
.  The attribute which described the risk of 
antibody formation is based on research which indicates that this is a risk for recombinant 
enzyme replacement therapies (ERT), but further work is underway
14
.  Neutralising antibody 
formation could theoretically lower the overall effectiveness of ERT
14
.  The potential risk for 
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developing antibodies is substantially reduced or even eliminated for small molecule 
treatments. The DCE methodology is well suited to exploring hypothetical or theoretical 
prospects as well as outcomes that are more concrete (such as route of administration).  
Therefore, it was included to provide some insight into this possible risk.  
 
The five attributes and associated levels were discussed with the clinical expert in Fabry 
disease.  Through this discussion there was a clear conclusion that the survey should include 
some description of treatment effectiveness in terms of overall survival (even though 
ĂǀĂŝůĂďůĞ ƚƌĞĂƚŵĞŶƚƐ ĚŽŶ ?ƚ ĚŝĨĨĞƌ ŝŶ ƚŚŝƐ ƌĞŐĂƌĚ ?. Differences in overall survival between 
ƚƌĞĂƚŵĞŶƚƐ ŚĞůƉƐ ƚŽ ĞŵƉŚĂƐŝƐĞ ƚŚĞ ŝŵƉŽƌƚĂŶĐĞ ŽĨ ƚŚĞ ƚƌĞĂƚŵĞŶƚ ĨŽƌ ŵĂŝŶƚĂŝŶŝŶŐ ƉĞŽƉůĞ ?Ɛ
health. The overall survival attribute was described in terms of 6 levels in order to provide 
as much sensitivity as possible to ƉĂƌƚŝĐŝƉĂŶƚƐ ? ƉƌĞĨĞƌĞŶĐĞ ĨƵŶĐƚŝŽŶƐ ? The attributes and 
levels were combined into choice sets using a published orthogonal fractional factorial array 
which had been folded over. The survey consisted of 36 pairs of choice sets, however in 
order to not overly burden participants, the choice sets were divided into two sets of 18 
choices, and participants were randomly assigned to one of the surveys. See Figure 1 for an 
example choice question.  
 
The survey included some background details regarding Fabry disease and how it affects 
people and how uncommon or rare the disease is.  This was designed to provide a frame of 
reference for when the participants subsequently were asked the choice questions.  A 
description was provided for each attribute as well, to help participants understand the 
attributes.  
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In addition to the choice questions, the survey was designed query participants using a 
series of background questions such as their age, sex and health status.  The survey also 
included a series of questions designed to capture participants attitudes regarding the risks 
and benefits of the treatment options and the extent to which cost should be considered as 
a factor when making decisions about the approval of drugs.  These questions were 
included to provide background information regarding the diversity of views in the general 
public.   
 
The draft survey was piloted with five members of the public.  Participants were asked to 
complete the survey and then take part in a cognitive debriefing interview.  During the 
interview, participants were asked about their understanding of the attributes and 
questions, and about how they decided on their answers on the treatment questions.  
Following the interviews some minor formatting and wording changes were made.  
 
Ethics, consent and permissions 
The study protocol was reviewed and approved by an independent review board: Salus IRB 
(date of approval: 10
th
 February 2016) prior to commencing the recruitment process. Study 
procedures were in accordance with the Declaration of Helsinki, all participants gave 
informed consent using an IRB approved consent form prior to taking part in the study. 
 
Participant recruitment 
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The study was designed to recruit a representative sample of the general public in the UK.  
The general public (rather than people with Fabry disease) were recruited because this 
study was done from a societal perspective.  Decision makers such as National institute of 
Health and Care Excellence (NICE) in the UK state that decisions should reflect the 
preferences of the general public because of the central role of taxation in funding health 
care.  Outcome measures like the widely used EQ-5D are based on societal preferences 
(rather than weights derived from patients).   
Survey participants were recruited through a specialist recruitment panel in the UK. 
Potential participants were contacted by e-mail with a link to the survey and screened for 
eligibility; participants were eligible if they were at least 18 years of age and lived in the UK. 
Participants completed the online survey themselves. Recruitment was designed to produce 
a representative sample of approximately 500 people from the general public in the UK. 
Procedures 
Prior to the survey, all participants gave informed consent online, participants were then 
directed to the survey. The survey design consisted of three parts: the first part of the 
ƐƵƌǀĞǇ ĐŽůůĞĐƚĞĚ ƉĂƌƚŝĐŝƉĂŶƚƐ ? ƐŽĐŝŽ-demographics; the second part of the survey assessed 
ƉĂƌƚŝĐŝƉĂŶƚƐ ?ƉƌĞĨĞƌĞŶĐĞƐĨŽƌĚŝĨĨĞƌĞŶƚĂƚƚƌŝďƵƚĞƐŽĨ&ĂďƌǇĚŝƐĞĂƐĞŵĞĚŝĐĂƚŝŽŶ (the DCE); the 
third part of the survey asked participants to indicate their level of agreement with a series 
of statements about treatments.   
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Statistical Analysis Plan 
Demographic and attitudinal data were analysed using descriptive statistics.  Discrete choice 
data were analysed using regression models which accommodated the nature of the data. 
Analysis was conducted using a mixed effects logit regression model.  The mixed effects 
logit model extends the standard conditional logit model by allowing one or more of the 
parameters in the model to be randomly distributed. The limitation of a conditional logit 
model is that it assumes respondents have the same preferences and therefore makes the 
assumption of independence of irrelevant alternatives which may not be true. The mixed 
effects logit model overcomes this limitation by allowing the coefficients in the model to 
vary across respondents. By doing this, it accounts for preference heterogeneity between 
respondents, i.e. respondents are allowed to have different preferences. Mixed logit models 
adjust the standard errors of utility estimates to account for repeated choices by the same 
individual. The model is estimated using the maximum simulated likelihood approach. 
 
In the analyses, all attributes were specified as random coefficients, and choice scenarios 
were identified using a grouping variable.  Then a higher level grouping was specified at the 
level of respondent to account for multiple choice scenarios per respondents and to account 
for preference heterogeneity. The life expectancy variable was specified as a continuous 
variable in terms of additional years of survival which took ŝŶƚŽĂĐĐŽƵŶƚďŽƚŚƚŚĞŝŶĚŝǀŝĚƵĂůƐ ?
current age and their conditional life expectancy given their age
15
. 
 
In this model, the preference strength associated with each attribute level was measured 
with respect to a reference level. Odds ratios and 95% confidence intervals were calculated 
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from the results of the logit analyses. Odds ratios were used to interpret the importance of 
each attribute. Significant odds ratios below 1 imply that the participants were less likely to 
choose treatments with this attribute level (compared to the reference); and values above 1 
imply that they are more likely to. Significance of each OR was assessed using a type 1 error 
cut-off of p<0.05 with two-tailed tests. 
 
Marginal rates of substitution (MRS) reflect the extent to which participants are willing to 
trade between treatment attributes, in turn reflecting the value of each attribute to the 
participant. They were calculated using the ratio of coefficients for two attributes. MRS 
indicates the extent to which participants are willing to forego a unit of one attribute to gain 
a unit in a different attribute.  
 
The MRS estimates were used to estimate HRQL weights for changes in treatment profiles 
which could be used to estimate Quality adjusted life years (QALYs).  The extent to which 
participants were willing to trade overall survival against the other attributes (in the DCE 
survey) was hypothesised to be analogous to a time trade off exercise.  Based on this 
assumption it was hypothesised that the MRS indicates the extent to which people are 
willing to trade some duration of overall survival in order to achieve a gain on another 
attribute such as avoiding 12 headaches a year for the rest of their life.   
 
Results 
A total of, 506 participants completed the survey. Demographics of the sample are 
summarised in Table 1. The sample approximately reflects the UK population demographics 
 13 
in terms of gender, age and ethnicity
16
. Just over half the participants indicated that they 
are normally healthy and do not require prescription medicine.  Thirty percent indicated 
that they took prescription medicine despite being fit and well and almost 20% indicated 
that they had a long-term illness that required prescription medication.  Just over 3% also 
indicated that they had some personal experience with a rare disease.   
Table 1 
 
Table 2 shows a summary of the extent to which people agreed or disagreed with a series of 
statements about NHS treatments.  There is a diversity of opinion regarding most questions.  
However, over 80% of participants recognised that treatments for rare diseases will 
inevitably be more expensive and generally people believed quite strongly in equitable 
access to treatments. There was also a recognition that the NHS cannot afford to pay for all 
treatments and must prioritise. Levels of agreement that treatments come with risks of side 
effects, and this risk may be higher for rare diseases were high. 
Table 2 
Preference data 
The results presented in Table 3 show that all of the attributes are significant predictors of 
choice and therefore each of the attributes was considered by respondents when they were 
making their decisions. The odds ratios provide some indication of the importance of each 
attribute.  Table 3 shows that participants were significantly more likely to choose a 
treatment which meant an increase in their life expectancy by 1 year (Odds Ratio = 1.574; 
95%CI=1.504-1.647).  Participants expressed a strong preference for an every other day 
tablet compared to the infusion treatment.  Participants also preferred to avoid treatments 
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with headaches and treatments with some form of treatment reaction (such as flu like 
symptoms).  Participants were perhaps least concerned about the risk of antibody 
formation. 
Table 3 
From this analysis the MRS were estimated so that it is possible to determine the extent to 
which participants were willing to trade years of life for avoidance of headaches, reactions, 
antibodies and treatment by infusion (compared to tablet).  The MRS are displayed in Table 
4, these represent the number of units of attributes that is equivalent to one year of 
additional life.   
Table 4 
To estimate utilities we proposed the following argument: If we have 2 treatments and one 
causes 12 headaches a year while the other has none and the treatments are the same in all 
other regards then the MRS tells us how many years of additional life participants will 
consider equivalent to having to also endure 12 headaches a year (for the rest of their life). 
The MRS data (Table 4), indicate that the difference between 0 and 12 headaches a year has 
the same weight as 1/0.61 years of life.  In the study sample with a mean age of 46.9 years 
and based on UK life expectancy it was estimated participants would have approximately 
34.6 years of life left [11]. Therefore, the utility loss associated with experiencing 12 
headaches a year is (1/0.61)/34.6 = 0.047.   
 
Stated another way: the MRS of 1/0.61 = 1.64 for 12 episodes of headache implies that a 
participant is willing to trade 1.64 years of life to avoid 12 episodes of headache every year 
for the rest of their lives.  Over a 34.6 year life span, assuming life in full health, this is 
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1.64/34.6= 0.047 loss of QALYs per year.  Respondents are indifferent between (a) 34.6 
years of life with 12 episodes of headache per year and (b) 32.96 years of life in full health 
(i.e. 34.6 years - 1.64).  Applying this rationale we have estimated utility weights for 
differences in attribute levels (Table 4).   
 
Discussion 
This report describes a stated preference survey designed to understand the value of 
innovations in treatment for Fabry disease.  The study suggests that the general public was 
willing to engage in this task and provided values with good face validity.  The DCE results 
show the importance of the attributes of treatment.  Overall survival is a very important 
attribute for participants, but the underlying DCE design and analysis allowed it to be 
concluded that participants still value improvements in the other attributes.  Participants 
placed significant value on moving to an oral therapy from regular infusions.  This perhaps 
reflects the bother or inconvenience of regular infusions which take up a lot of time, and are 
administered by needle (which many people prefer to avoid).  Regular infusions are also a 
significant on-going reminder that the person has Fabry disease.  A tablet taken every other 
day ĂƚďĞĚƚŝŵĞŚĂƐŵƵĐŚ ůĞƐƐ ŝŵƉĂĐƚŽŶƉĞŽƉůĞ ?Ɛ ůŝǀĞƐĂŶĚ ŝƐĐŽŶƐŝĚĞƌĂďůǇĞĂƐŝĞƌ ƚŽ ƚĂŬĞ ?
One way to consider these results is that if two treatments with equal efficacy differ 
according to the route of administration then our participants would strongly prefer the oral 
treatment. Furthermore the participants would prefer to avoid infusion reactions and any 
headaches associated with treatment.   
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In addition to route of administration, participants recognised the impact of treatment 
related reactions which can be experienced following an infusion.  Participants had a strong 
preference to avoid infusion reactions.  Participants also had a strong preference to avoid 
treatment related headaches even though it was noted that they could be treated with pain 
killers.  The effect of headaches and infusion reactions was considered broadly similar by 
the participants in this study.  Lastly, participants placed less weight on the risk of 
developing antibodies.  It was stated in the questionnaire that the actual risk of this is very 
unclear at the moment and its probable the valuations reflect that.   
The survey also includeĚƋƵĞƐƚŝŽŶƐƌĞŐĂƌĚŝŶŐƉĞŽƉůĞ ?ƐĂƚƚŝƚƵĚĞƐƚŽƚreatments in the health 
service.  Most people in the sample agreed that treatments for rare diseases will inevitably 
be more expensive. There was overall agreement that the NHS needs to consider cost when 
making decisions.  Interestingly the public also agreed with the theoretical statement that 
treatments for rare disease probably have more risk of side effects associated with them.  
These data provide some interesting context when considering the patient preference data.   
In the UK, the benefits of treatments are considered in terms of how they affect health-
related quality of life (HRQL) as well as length of life, which are combined into the quality 
adjusted life year (QALY) metric [13].  The HRQL data is often obtained from participants in 
clinical trials completing standardised measures such as the EQ-5D.  However in trials in rare 
diseases, adequate data are often not available due to the small sample sizes, making it 
difficult to aggregate the data and claim it is representative of patients with the disease in 
question.  Despite this, decision makers still request HRQL outcomes data to estimate QALYs 
to support economic evaluations.  This study tried to avoid the difficulties of estimating the 
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HRQL associated with side effects and mode of administration using a measure like EQ-5D 
by using the DCE data directly.  The data were used to explore the extent to which 
participants were willing to trade overall survival against other benefits of treatments.  This 
was hypothesised was analogous to the time trade off method and we applied that logic to 
estimate disutilities.  Preferences from a representative sample of the UK general public 
rather than people with Fabry disease were captured to provide a societal perspective.  In 
the UK, NICE state that they wish to see health outcomes data used in models which has 
been weighted by preferences from the general public
17
.  It is believed that this approach 
could be applied in other disease areas to understand the value of new treatments in rare 
disease.   
The resulting disutilites from this exercise appear to have some face validity.  But testing 
whether they are truly valid or accurate is difficult to achieve.  It would be possible to try to 
validate the results by estimating the same effects on HRQL using the EQ-5D.  However as 
already stated, being able to recruit a sufficiently large sample of Fabry patients to verify 
these effects would be very difficult.  Further work in other disease areas which are easier 
to verify would be a useful next step.  There are several issues to consider which may affect 
the accuracy of our estimates.  The DCE method may lead the participants to overly focus 
on some very specific issues.  Other important features of the different treatments for Fabry 
disease could have been included. For example, existing intravenous treatments for Fabry 
disease have a much longer history of use compared with the new oral treatment and so 
greater real world data regarding efficacy and toxicity are available for the drugs.  History of 
use data or other treatment attributes may be important to patients making treatment 
decisions but these attributes are missing from this study.  It would be interesting to verify 
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the weights given to our study attributes in a subsequent survey that also included other 
aspects of the disease such as history of use.  It would also be interesting to verify these 
findings in a study with Fabry patients.  This methodology does necessitate quite large 
samples of participants which would make it difficult to conduct in Fabry patients.  But 
leaving aside the practical problems, the preference weights from patients who have 
experienced intravenous (IV) therapy for many months or years would be a very interesting 
contrast to the public preference data here.  Such a study may provide some insight into 
whether people would prefer to remain on their current IV treatment even though they 
perhaps preferred oral therapy in the survey.    
The survey recruited the general public and we can only assume that prior to this study 
most were not aware of Fabry disease.  To provide context for the decisions they were 
asked to make, we provided a quite detailed background document about the disease.  
However it is unclear if the sample fully understood the nature of the questions they were 
being asked or indeed the nature of the condition.  The cognitive debrief data indicated 
good levels of understanding.  But in an online survey we cannot be certain that everyone 
read all of the information received or understand the information to the level of the 
participants in pilot study.  The DCE results have some face validity which suggests that 
people did understand what they were asked to do.  It is also worth commenting that even 
if people did not understand all of the complications of Fabry disease, they probably did 
understand the more tangible concepts such as headaches, treatment reactions and 
switching from an infusion treatment to a tablet.  We asked participants to define the 
relative importance of these factors so that we can better understand and determine 
whether these key issues and limitations can be addressed. The other main limitation 
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perhaps relates to the calculation of weights for QALY estimation.  The logic that was 
applied is outlined in the methods, which notwithstanding certain assumptions we believe 
are reasonably robust.  At the current time it is not been possible to test these assumptions, 
but future studies could do that quite usefully.     
Conclusions 
This stated preference survey shows the value that the general public place on innovations 
in treatments for Fabry disease.  The results show that overall survival, treatment 
effectiveness, route of administration, side effects, and risks of treatment related antibody 
formation are all significant drivers of choice.  The survey data was also used to estimate 
QALY weights for these attributes.  
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Table 1 Sample demographics 
  N=506 
Gender Female n (%) 257 (50.8%) 
Age Mean (SD) 46.93 (16.15) 
Ethnicity White British n (%) 416 (82.2%) 
Education No formal qualifications n (%) 31 (6.1%) 
GCSE/O levels n (%) 87 (17.2%) 
A levels or equivalent n (%) 86 (17.0%) 
Vocational qualifications n (%) 72 (14.2%) 
University degree n (%) 218 (43.1%) 
Other n (%) 12 (2.4%) 
Employment Employed full time n (%) 238 (47.0%) 
Employed part time n (%) 72 (14.2%) 
Looking after family n (%) 28 (5.5%) 
Retired n (%) 112 (22.1%) 
Seeking work/unemployed n (%) 14 (2.8%) 
Disabled n (%) 18 (3.6%) 
Student n (%) 18 (3.6%) 
Other n (%) 5 (1.0%) 
Prefer not to answer n (%) 1 (0.2%) 
General 
health 
Normally fit and well and do not take prescription medication 
n (%) 
268 (53.0%) 
Normally fit and well but do take prescription medication n 
(%) 
147 (29.1%) 
Long term illness that requires prescription medication n (%) 96 (19.0%) 
Diagnosed with a rare disease n (%) 8 (1.6%) 
Member of close family has a rare disease n (%) 9 (1.8%) 
N=number; SD=standard deviation 
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Table 2 Statements about NHS treatments 
 STRONGLY 
AGREE 
SLIGHTLY 
AGREE 
NOT SURE SLIGHTLY 
DISAGREE 
STRONGLY 
DISAGREE 
Treatments should only be used in the NHS if 
they are completely safe 
170 (33.6%) 190 (37.5%) 86 (17.0%) 56 (11.1%) 4 (0.8%) 
For all treatments we have to accept that 
there is always some risk of side effects 
229 (45.3%) 228 (45.1%) 43 (8.5%) 5 (1.0%) 1 (0.2%) 
I agree that treatments for rare diseases will 
inevitably be more expensive for the NHS 
231 (45.7%) 187 (37.0%) 74 (14.6%) 10 (2.0%) 4 (0.8%) 
When the NHS decides which treatments to 
buy they should consider the cost of the 
treatment as well as how effective it is. 
115 (22.7%) 193 (38.1%) 105 (20.8%) 65 (12.8%) 28 (5.5%) 
The NHS cannot afford to pay for all drugs 
and so should prioritise 
75 (14.8%) 179 (35.4%) 141 (27.9%) 68 (13.4%) 43 (8.5%) 
Decisions about treatment should be agreed 
between the doctor and the patient 
336 (66.4%) 125 (24.7%) 38 (7.5%) 5 (1.0%) 2 (0.4%) 
I accept that treatments for rare diseases 
probably have more risks of side effects 
198 (39.1%) 209 (41.3%) 79 (15.6%) 17 (3.4%) 3 (0.6%) 
Many people will be less likely to accept 
treatment by injection than a tablet 
120 (23.7%) 227 (44.9%) 115 (22.7%) 37 (7.3%) 7 (1.4%) 
Decisions taken by the NHS to fund a drug 
should be fair for all patients.   
288 (56.9%) 143 (28.3%) 64 (12.6%) 8 (1.6%) 3 (0.6%) 
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Table 3  Results of mixed logit but with transformed survival attribute which considers the value of an 
ĂĚĚŝƚŝŽŶĂůǇĞĂƌŽĨůŝĨĞǁŝƚŚƌĞƐƉĞĐƚƚŽĞĂĐŚƉĂƌƚŝĐŝƉĂŶƚƐ ?ĂŐĞĂŶĚƚŚĞŝƌƉƌĞĚŝĐƚĞĚŽǀĞƌĂůůƐƵƌǀŝǀĂů 
Variables Coefficients P>|z| Odds ratios 95% CI 
Remaining life expectancy in years (continuous variable)          
Increase in remaining life expectancy by one year 0.454 0.000 1.574 1.504 1.647 
Mode of administration (reference category: tablet)           
Nurse-administered infusion -0.816 0.000 0.442 0.406 0.482 
Self-administered infusion -0.853 0.000 0.426 0.384 0.474 
Reaction to the treatment (reference category: never 
experience a reaction to your treatment) 
        
Reaction to your treatment about 6 times a year -0.318 0.000 0.728 0.669 0.792 
Reaction to your treatment about 12 times a year -0.567 0.000 0.567 0.520 0.619 
Side effects: headache (reference category: No 
headaches from treatment) 
          
Headaches 6 times a year treatable with painkillers -0.448 0.000 0.639 0.587 0.696 
Headaches 12 times a year treatable with painkillers -0.742 0.000 0.476 0.435 0.522 
Long term use of treatment  (reference category: no 
known risk of developing antibodies) 
        
15% or under 1 in 7 people will develop antibodies in a 
few years 
-0.149 0.000 0.862 0.795 0.935 
25% or under 1 in 4 people will develop antibodies in a 
few years 
-0.437 0.000 0.646 0.573 0.730 
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Table 4  Estimated marginal rates of substitution and associated disutilities for differences in attribute 
levels 
 MRS Disutility 
Nurse-administered infusion (compared to oral tablet) 0.56 0.0520 
Self-administered infusion (compared to oral tablet) 0.53 0.0543 
Reaction to your treatment about 6 times a year (compared to no reaction) 1.43 0.0202 
Reaction to your treatment about 12 times a year (compared to no reaction) 0.80 0.0361 
Headaches 6 times a year treatable with painkillers (compared to no 
headache) 
1.01 0.0285 
Headaches 12 times a year treatable with painkillers (compared to no 
headache) 
0.61 0.0473 
15% or under 1 in 7 people will develop antibodies in a few years (compared to 
no antibodies) 
3.05 0.0095 
25% or under 1 in 4 people will develop antibodies in a few years(compared to 
no antibodies) 
1.04 0.0278 
 
 
